Prognostic impact of the 2015 world health organisation classification of lung adenocarcinoma : a study in departement specialized in thoracic pathology

##plugins.themes.academic_pro.article.sidebar##

Published Jun 12, 2018
Download
pdf
Vol. 96 No. 1 (2018): Issue Jan 2018

##plugins.themes.academic_pro.article.main##

Mona Mlika
Imen Helal
Ali Mrabet
Faouzi El Mezni

Abstract

Background: The 2015 WHO classification of primary lung adenocarcinomas idendified not only new subtypes but also new prognostic groups. Solid and micropapillary adenocarcinomas are considered of bad prognosis, lepidici adenocarcinomas are considered of good prognosis and acinary and papillary ones are considered of intermediate prognosis. We aimed to assess the prognostic relevance of this classification through the experience of a specialized Department in Thoracic Oncology.
Methods : We described a survival study about 101 patients presenting primary adenocarcinomas diagnosed between 2008 and 2011. Survival curves were compared using the Log-Rank test. In order to assess the prognostic impact of the classification, 3 groups were formes: group 1 included lepidic adenocarcinomas, le group 2 included acinary and papillary subtypes and group 3 included solid subtype. A univariate analysis was performed to assess the age, sex, size, vascular emboli, lymph nodes, pTNM, histologic subtypes, neoadjuvant treatment and adjuvant treatment. Multivariate analysis using COX model was performed.
Results : There was no significant difference between the different subtypes. Besides, the multivariate analysis revealed the pTNM (p=0,02)  stage and the adjuvant treatment (p=0,007) as relevant prognostic factors.
Conclusion : Our results are discordant with those reported in the literature. It seems that including large series is necessary in order to assess this prognostic classification.

Keywords:

adenocarcinoma, lung, prognosis, 2015 WHO

##plugins.themes.academic_pro.article.details##

References

  1. Siegel R, Naishadham D, Jemal A. cancer statistics,2013. CA Cancer J Clin. 2013;63:11-30.
  2. Registre des cancers Nord Tunisie. 2004-2006.
  3. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P et al. The novel histologic InternationalAssociation for the Study of Lung Cancer/American Thoracic Society/EuropeanRespiratory Society classification system of lung adenocarcinoma is astage-independent predictor of survival. J ClinOncol. 2012 May 1;30(13):1438-46.
  4. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer, 2015.
  5. Mlika M, Ayadi-Kaddour A, Boudaya S, Laabidi S, Boussen H, El Mezni F. [The new classification of lung adenocarcinomas according to the American Thoracic Society and the European Respiratory Society: new recommendations to improve management]. Tun Med. 2013;91:293-9.
  6. Urer HN, Kocaturk CI, Gunluoglu MZ, Arda N, Bedirhan MA, Fener N. Relationship between lung adenocarcinoma histological subtype and patient prognosis. Ann Thorac Cardiovasc Surg. 2014;20(1):12-8.
  7. Westaway DD, Toon CW, Farzin M, Sioson L, Watson N, Brady P. The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. Pathology. 2013 Oct;45(6):553-8.
  8. Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J ThoracOncol. 2013 Apr;8(4):461-8.
  9. Laroche C, Fairbairn I, Moss H, Pepke-Zaba J, Sharples L, Flower C et al. Role of computed tomographic scanning of the thorax prior to bronchoscopy in the investigation of suspected lung cancer. Thorax. 2000;55:359-63.
  10. Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013 Sep;81(3):371-6.
  11. Hung JJ, Yeh YC, Jeng WJ, Wu KJ, Huang BS, Wu YC et al. Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J ClinOncol. 2014 Aug1;32(22):2357-64.
  12. Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A et al. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest. 2014 Sep;146(3):633-43.
  13. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J ThoracOncol. 2013 May;8(5):612-8.
  14. Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011 May;24(5):653-64.
  15. Xu CH, Wang W, Wei Y, Hu HD, Zou J, Yan J et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma. Eur J SurgOncol. 2015 Oct;41(10):1430-6.
  16. Zhao ZR, Xi SY, Li W, Situ DR, Chen KM, Yang H, Su XD, Lin YB, Long H. Prognostic impact of pattern-based grading system by the new IASLC/ATS/ERS classification in Asian patients with stage I lung adenocarcinoma. Lung Cancer. 2015 Dec;90(3):604-9.
  17. Woo T, Okudela K, Mitsui H, Tajiri M, Yamamoto T, Rino Y. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathol Int. 2012 Dec;62(12):785-91.
  18. Murakami S, Ito H, Tsubokawa N, Mimae T, Sasada S, Yoshiya T. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma. Lung Cancer. 2015 Nov;90(2):199-204.
  19. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China. Eur J Surg Oncol. 2013 Nov;39(11):1262-8.
  20. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China. Eur J Surg Oncol. 2013 Nov;39(11):1262-8.
  21. Kadota K, Suzuki K, Kachala SS, Zabor EC, Sima CS, Moreira AL. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol. 2012 Aug;25(8):1117-27.
  22. Duhig EE, Dettrick A, Godbolt DB, Pauli J, van Zwieten A, Hansen AR. Mitosis trumps T stage and proposed international association for the study of lung cancer/american thoracic society/European respiratory society classification for prognostic value in resected stage 1 lung adenocarcinoma. J Thorac Oncol. 2015 Apr;10(4):673-81.